Transthera Sciences Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tinengotinib has been awarded orphan drug designation from the European Medicines Agency for use in select patients with biliary tract cancer.

South koreaUnited statesTransthera sciences incEuropean unionEuropean medicines agencyTransthera sciencesNorth americaEuropean medicinesDthera sciencesKankeu fonkouaOrphan drug designationBiliary tract cancerPhase 3 first 308 study nct05948475Physicians choice of treatment vs tinengotinibFgfr mutated cholangiocarcinoma